Evidence map›Paper›PMID 39985777›Full record

ArticleMolecular oncology2025

Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer.

Marina N Sharifi, Eric Feng, Nicholas R Rydzewski, Amy K Taylor, Jamie M Sperger, Yue Shi, Kyle T Helzer, Matthew L Bootsma, Viridiana Carreno, Alex H Chang and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Marina N SharifiCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Eric FengHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-0906-0558
Nicholas R RydzewskiDepartment of Human Oncology, University of Wisconsin-Madison, WI, USA.
Amy K TaylorCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Jamie M SpergerCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Yue ShiDepartment of Human Oncology, University of Wisconsin-Madison, WI, USA.
Kyle T HelzerDepartment of Human Oncology, University of Wisconsin-Madison, WI, USA.
Matthew L BootsmaDepartment of Human Oncology, University of Wisconsin-Madison, WI, USA.
Viridiana CarrenoDepartment of Medicine, University of Wisconsin-Madison, WI, USA.
Alex H ChangDepartment of Medicine, University of Wisconsin-Madison, WI, USA.
Luke A NunamakerCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Grace C BlitzerDepartment of Human Oncology, University of Wisconsin-Madison, WI, USA.
Tianfu Andy ShangDepartment of Human Oncology, University of Wisconsin-Madison, WI, USA.
Aishwarya SubramanianHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Anders BjartellDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Andreas JosefssonDepartment of Diagnostics and Interventions, Urology, Umeå University, Sweden.
Pernilla WikströmDepartment of Medical Biosciences, Pathology, Umeå University, Sweden.ORCID https://orcid.org/0000-0002-6347-1999
Emily FengHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Manish KohliHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Rendong YangDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Rahul AggarwalHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
David A QuigleyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Joshua M LangCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Shuang G ZhaoCarbone Cancer Center, University of Wisconsin-Madison, WI, USA.
Martin SjöströmHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-2629-9966

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
University of Wisconsin Prostate SPOREP50CA269011 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DAVID F. JARRARD, DOUGLAS G. MCNEEL · 2023 to 2026
$10.6M
UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate CancerP50CA275741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lawrence Fong · 2024 to 2026
$8.8M
The Molecular Drivers and Therapeutic Susceptibilities in Lineage State Transitions of Metastatic Prostate CancerP01CA298991 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Joshua Lang · 2025 to 2026
$7.6M
AR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9M
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase MicrofluidicsR01CA247479 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEEBE, DAVID J, LANG, JOSHUA MICHAEL · 2020 to 2024
$3.1M
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic nichesR01CA276269 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Scott M. Dehm, Joshua Lang · 2023 to 2026
$2.6M
Computational approaches to delineate non-canonical splicing eventsR35GM142441 · NIGMS · UNIVERSITY OF MINNESOTA · PI YANG, RENDONG · 2021 to 2025
$2.0M
Targeting early events in prostate cancer lineage plasticityR01CA270539 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2023 to 2026
$1.8M
Genome-wide mapping and characterization of exitrons in human cancerR01CA259388 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Rendong Yang · 2022 to 2026
$1.8M
Validation of predictive liquid biomarkers for patients with metastatic prostate cancerUH2CA260389 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ARMSTRONG, ANDREW J, HALABI, SUSAN · 2021 to 2022
$352k
The next generation of liquid biopsies: Predictive and pharmacologic biomarkersR50CA293840 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jamie M Sperger · 2024 to 2026
$312k
Benioff Initiative for Prostate Cancer ResearchCancerfonden 21 1856 PjCancerfonden Junior Clinical Investigator AwardDepartment of Defense HT94252410252Department of Defense PC180469Department of Defense PC190039Department of Defense PC200334Department of Defense PC220240Department of Defense W81XWH-22-1-0833Doris Duke Charitable Foundation 2021088Hjelms Stiftelse för medicinsk forskningKnut och Alice Wallenbergs StiftelseNCI NIH HHS P01 CA298991NCI NIH HHS P30 CA014520NCI NIH HHS P50 CA269011NCI NIH HHS P50 CA275741NCI NIH HHS R01 CA174777NCI NIH HHS R01 CA247479NCI NIH HHS R01 CA259388NCI NIH HHS R01 CA270539NCI NIH HHS R01 CA276269NCI NIH HHS R50 CA293840NCI NIH HHS UH2 CA260389NIGMS NIH HHS R35 GM142441NIH HHS 1P50CA275741NIH HHS 1UH2CA260389NIH HHS DP2 OD030734NIH HHS P30 CA014520NIH HHS R01CA174777NIH HHS R01CA247479NIH HHS R01CA259388NIH HHS R01CA270539NIH HHS R01CA276269NIH HHS R35GM142441ProstatacancerförbundetProstate Cancer FoundationUniversity of Wisconsin Office of the Vice Chancellor
6 · The paper itself

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression-based pathways with clinical outcomes and intrapatient and intratumor heterogeneity. Survival data were obtained for 272 patients. Pathway-level enrichment was evaluated using gene set variation analysis. scRNA-seq datasets from mCRPC tissue biopsies and circulating tumor cells were used to investigate heterogeneity of adverse pathways. We identified five pathway clusters: (a) Immune response/WNT/TGF-beta signaling, (b) AR signaling/luminal signatures, (c) mTOR signaling and glycolysis, (d) cell proliferation, and (e) neuroendocrine differentiation. Proliferation, AR signaling loss, and glycolysis/mTOR signaling were independently prognostic. Adverse prognostic pathway scores decreased on treatment with AR signaling inhibitors, but not at progression, suggesting failure to permanently target these pathways. scRNA-seq datasets from mCRPC tissue biopsies and circulating tumor cells were used to investigate heterogeneity of adverse pathways. Our results suggest loss of AR signaling, high proliferation, and a glycolytic phenotype as adverse prognostic pathways in mCRPC that could be used in conjunction with clinical factors to prognosticate for treatment decisions.

Indexed as

Gene Expression Regulation, NeoplasticProstatic Neoplasms, Castration-ResistantAgedGene Expression ProfilingGlycolysisHumansMaleMiddle AgedNeoplasm MetastasisPrognosisSignal Transductionbiomarkergene expressionmetastatic castration‐resistant prostate cancerprecision medicineprognosis

Identifiers

PMID39985777
PMCPMC12330944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.